PuMP: Oncolytic HSV1 MVR-C5252 in Patients with rHGG (Recurrent Glioma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how safe and effective an experimental drug called MVR-C5252 (the study drug) is for people with advanced brain cancer.

What is the Condition Being Studied?

Malignant Glioma

Who Can Participate in the Study?

Adults ages 18+ who are diagnosed with recurrent high-grade glioma.

For more information about this study, please call 919-668-3726.

Age Group

What is Involved?

If you join the study, you will:

  • Have a physical and neurological exam and other tests
  • Have magnetic resonance imaging (MRI) of the brain
  • Have blood draws
  • Have brain tumor biopsy and testing of tumor sample
  • Have a catheter (small flexible tube) placed in and around the tumor with the other end of the catheter extending slightly outside of the head
  • Get the study drug infused through an external pump and the implanted catheter

Study Details

Full Title
The PuMP Trial: A Multistage Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 in Patients with Recurrent High-Grade Glioma
Principal Investigator
Protocol Number
IRB: PRO00112883
NCT: NCT06126744
Phase I
Enrollment Status
Open for Enrollment